8. **Klennert MD**, Price MR, Liu AH, *et al*. Morbidity patterns among low-income wheezing infants. *Pediatrics* 2003;**112**:49–57.
9. **International Study of Asthma and Allergies in Childhood (ISAAC) Steering Committee**. Worldwide variation in prevalence of symptoms of asthma, Allergic rhinoconjunctivitis, and atopic eczema: ISAAC. *Lancet* 1998;**351**:1225–32.
10. **Pearce N**, Ait-Khaled N, Beasley R, *et al*. Worldwide trends in the prevalence of asthma symptoms: phase III of the International Study of Asthma and Allergies in Childhood (ISAAC). *Thorax* 2007;**62**:758–66.
11. **Mallol J**, Garcia-Marcos L, Aguirre V, *et al*. The International Study of Wheezing in Infants: questionnaire validation. *Int Arch Allergy Immunol* 2007;**144**:44–50.
12. **Chong Neto HJ**, Rosario N, Dela Bianca AC, *et al*. Validation of a questionnaire for epidemiologic studies of wheezing in infants. *Pediatr Allergy Immunol* 2007;**18**:86–7.
13. **Ellwood P**, Asher MI, Beasley R, *et al*. The International Study of Asthma and Allergies in Childhood (ISAAC): phase three rationale and methods. *Int J Tuberc Lung Dis* 2005;**9**:10–16.
14. **Asher M**, Keil U, Anderson H, *et al*. International Study of Asthma and Allergies in Childhood (ISAAC): rationale and methods. *Eur Respir J* 1995;**8**:483–91.
15. **Brand PL**, Baraldi E, Bisgaard H, *et al*. Definition, assessment and treatment of wheezing disorders in preschool children: an evidence-based approach. *Eur Respir J* 2008;**32**:1096–110.
16. **Kaditis AG**, Winnie G, Syrogiannopoulos GA. Anti-inflammatory pharmacotherapy for wheezing in preschool children. *Pediatr Pulmonol* 2007;**42**:407–20.
17. **Legg JP**, Warner JA, Johnston SL, *et al*. Frequency of detection of picornaviruses and seven other respiratory pathogens in infants. *Pediatr Infect Dis J* 2005;**24**:611–16.
18. **Gern JE**, Brooks GD, Meyer P, *et al*. Bidirectional interactions between viral respiratory illnesses and cytokine responses in the first year of life. *J Allergy Clin Immunol* 2006;**117**:72–8.
19. **Lemanske RF Jr**, Jackson DJ, Gangnon RE, *et al*. Rhinovirus illnesses during infancy predict subsequent childhood wheezing. *J Allergy Clin Immunol* 2005;**116**:571–7.
20. **Kotaniemi-Syrjänen A**, Vainionpää R, Reijonen TM, *et al*. Rhinovirus-induced wheezing in infancy—the first sign of childhood asthma? *J Allergy Clin Immunol* 2003;**111**:66–71.
21. **Johnston SL**, Pattemore PK, Sanderson G, *et al*. Community study of role of viral infections in exacerbations of asthma in 9–11 year old children. *BMJ* 1995;**310**:1225–8.
22. **British Thoracic Society, Scottish Intercollegiate Guidelines Network (SIGN)**. British guideline on the management of asthma, 2008. http://www.brit-thoracic.org.uk/Portals/0/Clinical%20Information/Asthma/Guidelines/asthma_final2008.pdf (accessed Jun 2010).
23. **National Asthma Education and Prevention Program (NAEPP), National Heart, Lung, and Blood Institute (NHLBI), National Institutes of Health (NIH)**. Guidelines for the diagnosis and management of asthma, 2007. http://www.nhlbi.nih.gov/guidelines/asthma/08_sec4_it_0-11.pdf (accessed Jun 2010).
24. **Castro-Rodríguez JA**, Holberg CJ, Wright AL, *et al*. A clinical index to define risk of asthma in young children with recurrent wheezing. *Am J Respir Crit Care Med* 2000;**162**:1403–6.

Pulmonary puzzle

Persistent cough: an unusual cause

A 55-year-old Caucasian man who worked in the recycling industry presented with a 7-month history of non-productive cough and no other symptoms. He had no significant previous medical history and took no medications. He had never smoked and had no history of travel outside the UK. He described symptoms of a lower respiratory tract infection 5 months previously which had been treated with antibiotics and steroids. A chest x-ray at the time had shown consolidation consistent

with infection which had subsequently resolved. Physical examination was normal.

Spirometry and transfer factor were normal. Full blood count showed isolated eosinophilia of $12.7 \times 10^{-9}/l$. The blood film revealed an unremarkable cell morphology. The erythrocyte sedimentation rate was elevated at 92 mm/h. Urea and electrolytes, liver function tests and serum immunoglobulin E (IgE) were normal. Aspergillus precipitins, antineutrophil cytoplasmic antibodies, rheumatoid factor and antinuclear antibodies were negative. Stool culture and microscopy were negative. A repeat chest x-ray was normal but a high-resolution CT scan showed bilateral patchy bronchocentric consolidation (figure 1) and mild splenomegaly. Bronchoscopy revealed no endobronchial abnormality with negative results for culture and cytology.

The patient's cough became so debilitating that he was unable to work. His eosinophil count rose to $18 \times 10^{-9}/l$ and he was referred for haematology review. A bone marrow trephine was performed and peripheral blood was sent for cytogenetic testing which gave the diagnosis. Within 2 weeks of commencing treatment his cough had resolved and his eosinophil count was 0.

QUESTION

What is the diagnosis and what treatment caused his dramatic clinical improvement?

See page 1024 for answer

Bethan Barker¹, Harmesh Moudgil², Gareth Slocombe³, Koottalai Srinivasan²

¹Department of Respiratory Medicine, Birmingham Heartlands Hospital, Bordesley Green East, Birmingham, UK; ²Department of Respiratory Medicine, Princess Royal Hospital, Apley Castle, Telford, UK; ³Department of Haematology, Princess Royal Hospital, Apley Castle, Telford, UK

Correspondence to Dr Bethan Barker, Department of Respiratory Medicine, Birmingham Heartlands Hospital, Bordesley Green East, Birmingham B9 5SS, UK; bethanbarker@hotmail.com

Competing interests None.

Patient consent Obtained.

Provenance and peer review Not commissioned; externally peer reviewed.

Thorax 2010;**65**:1009. doi:10.1136/thx.2010.135251

Figure 1 High-resolution CT scan showing bilateral patchy bronchocentric consolidation.

19. **Eklund A**, Blaschke E. Relationship between changed alveolar-capillary permeability and angiotensin converting enzyme activity in serum in sarcoidosis. *Thorax* 1986;**41**:629–34.
20. **Cozens AL**, Yezzi MJ, Kunzelmann K, *et al*. CFTR expression and chloride secretion in polarized immortal human bronchial epithelial cells. *Am J Respir Cell Mol Biol* 1994;**10**:38–47.
21. **Frenzel KE**, Falls DL. Neuregulin-1 proteins in rat brain and transfected cells are localized to lipid rafts. *J Neurochem* 2001;**77**:1–12.
22. **Law AJ**, Shannon Weickert C, Hyde TM, *et al*. Neuregulin-1 (NRG-1) mRNA and protein in the adult human brain. *Neuroscience* 2004;**127**:125–36.
23. **Bao J**, Lin H, Ouyang Y, *et al*. Activity-dependent transcription regulation of PSD-95 by neuregulin-1 and Eos. *Nat Neurosci* 2004;**7**:1250–8.
24. **Moller DR**, Forman JD, Liu MC, *et al*. Enhanced expression of IL-12 associated with Th1 cytokine profiles in active pulmonary sarcoidosis. *J Immunol* 1996;**156**:4952–60.
25. **Hauber HP**, Gholami D, Meyer A, *et al*. Increased interleukin-13 expression in patients with sarcoidosis. *Thorax* 2003;**58**:519–24.
26. **Cho JA**, Lee YS, Kim SH, *et al*. MHC independent anti-tumor immune responses induced by Hsp70-enriched exosomes generate tumor regression in murine models. *Cancer Lett* 2009;**275**:256–65.
27. **Engering A**, Pieters J. Association of distinct tetraspanins with MHC class II molecules at different subcellular locations in human immature dendritic cells. *Int Immunol* 2001;**13**:127–34.
28. **Qazi KR**, Gehrman U, Domange Jordo E, *et al*. Antigen-loaded exosomes alone induce Th1-type memory through a B-cell-dependent mechanism. *Blood* 2009;**113**:2673–83.
29. **Fazel SB**, Howie SE, Krajewski AS, *et al*. B lymphocyte accumulations in human pulmonary sarcoidosis. *Thorax* 1992;**47**:964–7.
30. **Laurendeau I**, Ferrer M, Garrido D, *et al*. Gene expression profiling of ErbB receptors and ligands in human meningiomas. *Cancer Invest* 2009;**27**:691–8.
31. **Patel NV**, Acarregui MJ, Snyder JM, *et al*. Neuregulin-1 and human epidermal growth factor receptors 2 and 3 play a role in human lung development in vitro. *Am J Respir Cell Mol Biol* 2000;**22**:432–40.
32. **Askling J**, Grunewald J, Eklund A, *et al*. Increased risk for cancer following sarcoidosis. *Am J Respir Crit Care Med* 1999;**160**:1668–72.
33. **Mathew S**, Bauer KL, Fischroeder A, *et al*. The anergic state in sarcoidosis is associated with diminished dendritic cell function. *J Immunol* 2008;**181**:746–55.
34. **Wickremasinghe MI**, Thomas LH, Friedland JS. Pulmonary epithelial cells are a source of IL-8 in the response to Mycobacterium tuberculosis: essential role of IL-1 from infected monocytes in a NF-kappa B-dependent network. *J Immunol* 1999;**163**:3936–47.
35. **Obregon C**, Rothen-Rutishauser B, Gerber P, *et al*. Active uptake of dendritic cell-derived exosomes by epithelial cells induces the release of inflammatory mediators through a TNF-alpha-mediated pathway. *Am J Pathol* 2009;**175**:696–705.

Pulmonary puzzle

ANSWER

From the question on page 1009

The combination of blood eosinophilia persisting for more than 6 months, end-organ damage as demonstrated by lung consolidation and an identified clonal chromosomal abnormality (ie, the FIP1L1/PDGFR α gene arrangement) fulfils the diagnostic criteria for chronic eosinophilic leukaemia (CEL).¹ In the absence of clonal chromosomal abnormalities, our patient would fulfil the criteria for an idiopathic hypereosinophilic syndrome (HES). The lack of relevant travel history along with normal IgE excluded tropical pulmonary eosinophilia as the diagnosis.²

The FIP1L1-PDGFR α fusion protein is a constitutively activated tyrosine kinase³ which occurs due to a deletion on chromosome 4q12. Expression of FIP1L1-PDGFR α in haematopoietic progenitors induces cytokine-independent differentiation of several myeloid lineages, not just eosinophils. Murine studies show that overexpression of interleukin 5 (IL-5) in the presence of FIP1L1-PDGFR α is required to induce eosinophilic tissue infiltration,⁴ with studies of human CD34 cells further suggesting that IL-5 helps induce the phenotype but alone is insufficient to induce HES/CEL-like disease.⁵

Treatment was with the tyrosine kinase inhibitor imatinib. Fifteen-year survival in HES prior to imatinib was around 42%. However, imatinib has been shown to induce clinical, haematological and molecular remission in the majority of patients and it is anticipated that long-term survival will significantly improve.³

The mechanism for cough in CEL is unknown. We did not demonstrate eosinophilic lung infiltration (no bronchial biopsies

or bronchoalveolar lavage were performed), but suggest that the pulmonary infiltrates seen on the CT scan represent eosinophilic infiltration. This would be consistent with a case of FIP1L1/PDGFR α -related disease who presented with cough,⁶ in whom CT scanning showed thickened airways and endobronchial biopsy showed eosinophilic inflammation. The patient also had normal spirometry and a negative histamine challenge test but a sensitive cough response to inhaled capsaicin. We hypothesise that eosinophils or their degranulation products are the cause of the cough, but further studies are required to elucidate exactly how eosinophils induce cough.

Thorax 2010;**65**:1024. doi:10.1136/thx.2010.135251

REFERENCES

1. **Bain B**, Pierre R, Imbert M, *et al*. Chronic eosinophilic leukaemia and the hypereosinophilic syndrome. In: Jaffe ES, Harris NL, Stein H, *et al*, eds. *World Health Organization classification of tumours: pathology and genetics of tumours of haematopoietic and lymphoid tissues*. Lyon, France: IARC Press, 2001:29–31.
2. **Ottesen EA**, Nutman TB. Tropical pulmonary eosinophilia. *Annu Rev Med* 1992;**43**:417–24.
3. **Cools J**, DeAngelo DJ, Gotlib J, *et al*. A tyrosine kinase created by fusion of positive PDGFR α and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. *N Engl J Med* 2003;**348**:1201–14.
4. **Yamada Y**, Rothenberg ME, Lee AW, *et al*. The FIP1L1-PDGFR α fusion gene cooperates with IL-5 to induce murine hypereosinophilic syndrome (HES)/chronic eosinophilic leukaemia(CEL)-like disease. *Blood* 2006;**107**:4071–9.
5. **Buitenhuis M**, Verhagen LP, Cools J, *et al*. Molecular mechanisms underlying FIP1L1-PDGFR α -mediated myeloproliferation. *Cancer Res* 2007;**67**:3759–66.
6. **Chung KF**, Hew M, Score J, *et al*. Cough and hypereosinophilia due to FIP1L1-PDGFR α fusion gene with tyrosine kinase activity. *Eur Respir J* 2006;**27**:230–2.